The correlation between tumor-associated macrophage infiltration and progression in cervical carcinoma.
Cervical cancer
Clinicopathological features
Meta-analysis
Progression
Tumor-associated macrophage (TAM)
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
28 05 2021
28 05 2021
Historique:
received:
23
09
2020
revised:
12
04
2021
accepted:
29
04
2021
pubmed:
1
5
2021
medline:
21
12
2021
entrez:
30
4
2021
Statut:
ppublish
Résumé
Tumor microenvironment (TME) plays a particularly important role in the progression, invasion and metastasis of cervical carcinoma (CC). Tumor-associated macrophages (TAMs) are significant components of the tumor microenvironment in CC. However, the results of studies on the correlation between TAMs and progression in CC are still controversial. This research aimed to investigate the relationship between TAMs infiltration and progression in CC. A total of 100 patients with CC were included in the study. The correlation between TAMs and clinicopathologic features was studied. Besides, a systematic literature search was conducted from legitimate electronic databases to specifically evaluate the role of TAMs in TME of cervical carcinoma. In the meta-analysis, high stromal CD68+ TAMs density was relevant to lymph node metastasis (WMD = 11.89, 95% CI: 5.30-18.47). At the same time, CD163+ M2 TAM density was associated with lymph node metastasis (OR = 2.42, 95% CI: 1.09-5.37; WMD = 39.37, 95% CI: 28.25-50.49) and FIGO stage (WMD = -33.60, 95% CI: -45.04 to -22.16). This was further confirmed in the experimental study of 100 tissues of cervical cancer. It supported a critical role of TAMs as a prospective predictor of cervical cancer. In conclusion, CD68+ TAM and CD163+ M2 TAM infiltration in CC were associated with tumor progression. And CD163+ M2 TAM infiltration was associated with more advanced FIGO stage and lymph node metastasis in CC.
Identifiants
pubmed: 33928349
pii: 228475
doi: 10.1042/BSR20203145
pmc: PMC8493445
pii:
doi:
Substances chimiques
Antigens, CD
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2021 The Author(s).
Références
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
Cancer Sci. 2018 Mar;109(3):863-870
pubmed: 29274107
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Pathol. 2002 Mar;196(3):254-65
pubmed: 11857487
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Clin Dev Immunol. 2012;2012:948098
pubmed: 22778768
J Transl Med. 2011 Dec 16;9:216
pubmed: 22176642
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Cell Physiol. 2013 Jul;228(7):1404-12
pubmed: 23065796
APMIS. 2014 Nov;122(11):1059-69
pubmed: 24698523
J Pathol. 2008 Sep;216(1):15-24
pubmed: 18553315
Gynecol Oncol. 2007 Apr;105(1):157-65
pubmed: 17229459
PLoS One. 2015 Sep 03;10(9):e0136654
pubmed: 26335330
Int J Gynaecol Obstet. 2017 Dec;139(3):346-351
pubmed: 28884821
Cancer Cell. 2015 Apr 13;27(4):462-72
pubmed: 25858805
Biomed Res Int. 2020 Jan 29;2020:6842963
pubmed: 32083131
Cancer. 2007 Feb 1;109(3):556-65
pubmed: 17177206
Trends Immunol. 2012 Mar;33(3):119-26
pubmed: 22277903
J Cancer. 2017 Oct 17;8(18):3868-3875
pubmed: 29151975
Immunity. 2010 May 28;32(5):593-604
pubmed: 20510870
Mol Carcinog. 2019 Mar;58(3):388-397
pubmed: 30362630
Signal Transduct Target Ther. 2021 Feb 23;6(1):75
pubmed: 33619259
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Arterioscler Thromb Vasc Biol. 2017 Jan;37(1):35-42
pubmed: 27765768
Pathol Int. 2010 Apr;60(4):278-83
pubmed: 20403029
Oncoimmunology. 2013 Apr 1;2(4):e23493
pubmed: 23734310
Scientifica (Cairo). 2015;2015:851252
pubmed: 26491604
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087
Ann Transl Med. 2016 Jul;4(14):263
pubmed: 27563650